Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Blockade Reversal in Chinese and Caucasian Subjects
NCT00825812Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Primary completion
- Sep 2010
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 3, randomised, single-blind trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Merck & Co. Primary endpoint: Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9. Started Jan 2010; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT00825812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00825812.